- Home
- BCDA vs CHRO Comparison
BCDA vs CHRO Comparison
Compare BCDA & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- CHRO
- Stock Information
- Founded
- BCDA N/A
- CHRO 2002
- Country
- BCDA United States
- CHRO United States
- Employees
- BCDA N/A
- CHRO N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- CHRO
- Sector
- BCDA Health Care
- CHRO
- Exchange
- BCDA Nasdaq
- CHRO Nasdaq
- Market Cap
- BCDA 9.4M
- CHRO 8.1M
- IPO Year
- BCDA N/A
- CHRO 2024
- Fundamental
- Price
- BCDA $1.92
- CHRO $1.35
- Analyst Decision
- BCDA Strong Buy
- CHRO Strong Buy
- Analyst Count
- BCDA 1
- CHRO 1
- Target Price
- BCDA $25.00
- CHRO N/A
- AVG Volume (30 Days)
- BCDA 93.6K
- CHRO 2.0M
- Earning Date
- BCDA 05-13-2025
- CHRO 05-14-2025
- Dividend Yield
- BCDA N/A
- CHRO N/A
- EPS Growth
- BCDA N/A
- CHRO N/A
- EPS
- BCDA N/A
- CHRO N/A
- Revenue
- BCDA $58,000.00
- CHRO N/A
- Revenue This Year
- BCDA N/A
- CHRO N/A
- Revenue Next Year
- BCDA N/A
- CHRO N/A
- P/E Ratio
- BCDA N/A
- CHRO N/A
- Revenue Growth
- BCDA N/A
- CHRO N/A
- 52 Week Low
- BCDA $1.63
- CHRO $0.45
- 52 Week High
- BCDA $6.15
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- BCDA 38.14
- CHRO 46.67
- Support Level
- BCDA $1.73
- CHRO $1.29
- Resistance Level
- BCDA $1.93
- CHRO $1.65
- Average True Range (ATR)
- BCDA 0.13
- CHRO 0.19
- MACD
- BCDA -0.01
- CHRO 0.02
- Stochastic Oscillator
- BCDA 30.95
- CHRO 13.79
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.